Inventor · disambiguated record
Jeffrey Engelman
Also filed as: ENGELMAN JEFFREY · ENGELMAN JEFFREY A · ENGELMAN JEFFREY ADAM
3 granted patents·7 pending applications·10 citations·filing 2008–2023
59Inventor score
Top patents by PatentIndex Score
10 records- 0182US8715665B2Methods for treating cancer resistant to ErbB therapeuticsJANNE PASI A·Filed 2008·Granted May 6, 2014·10 cites·12 claims
- 0268US2024287091A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 0368US2025276981A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 0462US12053470B2Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitorNOVARTIS AG·Filed 2022·Granted Aug 6, 2024·0 cites·7 claims
- 0560US11008620B2Methods for treating cancer resistant to ErbB therapeuticsDANA FARBER CANCER INST INC·Filed 2015·Granted May 18, 2021·0 cites·20 claims
- 0660US2025270191A1Quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 0755US2014296100A1Methods for treating cancer resistant to erbb therapeuticsDANA FARBER CANCER INST INC·Filed 2014·Application pending·0 cites
- 0853US2024082218A1Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancersNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0942US2019343836A1Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1031US2020237773A1Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey Engelman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →